blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2968227

EP2968227 - S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.12.2019
Database last updated on 05.08.2024
FormerThe patent has been granted
Status updated on  11.01.2019
FormerGrant of patent is intended
Status updated on  20.09.2018
FormerExamination is in progress
Status updated on  29.12.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Coats, Andrew J.S.
78/151 Fitzroy Street
St. Kilda Victoria 3182 / AU
For all designated states
Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin / DE
[2016/03]
Inventor(s)01 / COATS, Andrew J.S.
78/151 Fitzroy Street
St. Kilda, Victoria 3182 / AU
02 / ANKER, Stefan
Oberseestrasse 91
13053 Berlin / DE
03 / SPRINGER, Jochen
Mainstr. 1B
14612 Falkensee / DE
 [2016/03]
Representative(s)Gulde & Partner
Patent- und Rechtsanwaltskanzlei mbB
Wallstraße 58/59
10179 Berlin / DE
[2016/03]
Application number, filing date14764992.514.03.2014
[2016/03]
WO2014AU00274
Priority number, dateUS201361786235P14.03.2013         Original published format: US 201361786235 P
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014138814
Date:18.09.2014
Language:EN
[2014/38]
Type: A1 Application with search report 
No.:EP2968227
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2968227
Date:13.02.2019
Language:EN
[2019/07]
Search report(s)International search report - published on:AU18.09.2014
(Supplementary) European search report - dispatched on:EP27.09.2016
ClassificationIPC:A61K31/138, A61K31/165, A61K31/404, A61P25/28
[2016/03]
CPC:
A61K31/138 (EP,US); A61P25/28 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:S-ENANTIOMERENANGEREICHERTE ZUSAMMENSETZUNGEN VON BETABLOCKERN ZUR BEHANDLUNG VON AMYOTROPHER LATERALSKLEROSE[2016/03]
English:S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS[2016/03]
French:COMPOSITIONS DE BÊTAS BLOQUANTS ENRICHIES DU POINT DE VUE DES ÉNANTIOMÈRES-S POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE[2016/03]
Entry into regional phase06.10.2015National basic fee paid 
06.10.2015Search fee paid 
06.10.2015Designation fee(s) paid 
06.10.2015Examination fee paid 
Examination procedure06.10.2015Examination requested  [2016/03]
03.04.2017Amendment by applicant (claims and/or description)
04.01.2018Despatch of a communication from the examining division (Time limit: M04)
09.04.2018Reply to a communication from the examining division
21.09.2018Communication of intention to grant the patent
21.12.2018Fee for grant paid
21.12.2018Fee for publishing/printing paid
21.12.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.01.2018
Opposition(s)14.11.2019No opposition filed within time limit [2020/04]
Fees paidRenewal fee
30.03.2016Renewal fee patent year 03
30.03.2017Renewal fee patent year 04
28.03.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.03.2014
AL13.02.2019
CY13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
MC13.02.2019
MK13.02.2019
RO13.02.2019
RS13.02.2019
SI13.02.2019
SK13.02.2019
SM13.02.2019
MT14.03.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
[2022/31]
Former [2021/32]HU14.03.2014
AL13.02.2019
CY13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
MC13.02.2019
RO13.02.2019
RS13.02.2019
SI13.02.2019
SK13.02.2019
SM13.02.2019
MT14.03.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2021/26]AL13.02.2019
CY13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
MC13.02.2019
RO13.02.2019
RS13.02.2019
SI13.02.2019
SK13.02.2019
SM13.02.2019
MT14.03.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2020/29]AL13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
MC13.02.2019
RO13.02.2019
RS13.02.2019
SI13.02.2019
SK13.02.2019
SM13.02.2019
MT14.03.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2020/13]AL13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
MC13.02.2019
RO13.02.2019
RS13.02.2019
SI13.02.2019
SK13.02.2019
SM13.02.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2020/02]AL13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
MC13.02.2019
RO13.02.2019
RS13.02.2019
SK13.02.2019
SM13.02.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2019/51]AL13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
RO13.02.2019
RS13.02.2019
SK13.02.2019
SM13.02.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2019/49]AL13.02.2019
CZ13.02.2019
EE13.02.2019
FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
RO13.02.2019
RS13.02.2019
SK13.02.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2019/39]FI13.02.2019
HR13.02.2019
LT13.02.2019
LV13.02.2019
RS13.02.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
IS13.06.2019
Former [2019/38]FI13.02.2019
LT13.02.2019
BG13.05.2019
NO13.05.2019
GR14.05.2019
Former [2019/37]FI13.02.2019
LT13.02.2019
NO13.05.2019
GR14.05.2019
Former [2019/33]FI13.02.2019
LT13.02.2019
NO13.05.2019
Documents cited:Search[X]CN101323580  ;
 [X]EP0930291  (DAISO CO LTD [JP]) [X] 10,11 * column 1, paragraph 1; example 2 *;
 [X]US2005143378  (YUN ANTHONY J [US], et al) [X] 1-11 * page 2, paragraph 16 * * page 12, paragraph 88 * * page 20, paragraph 190; claims 1,21,29 *;
 [X]WO2007014219  (CURAVITA CORP [US], et al) [X] 1-11 * page 2, line 12 - page 3, line 27 * * page 13, line 12 - line 22 * * page 14, line 19 - page 15, line 16 * * example -; claims 1,4,5,9-11,3 *;
 [X]  - HAMPTON T G ET AL, "Propranolol attenuates sympathetic hyperfunction, delays motor dysfunction, and prolongs life in a mouse model of amyotrophic lateral sclerosis", EUROPEAN HEART JOURNAL, & 28TH CONGRESS OF THE EUROPEAN-SOCIETY-OF-CARDIOLOGY/WORLD CONGRESS OF CARDIOLOGY; BARCELONA, SPAIN; SEPTEMBER 02 -06, 2006, (200608), vol. 27, no. Suppl. 1, page 962, XP002761890 [X] 1,2,5-7,9,10 * the whole document *
 [X]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2009, no. 13, Database accession no. 2009-B43243, XP002761891 & CN101323580 A 20081217 (UNIV HEBEI SCI & TECHNOLOGY) [X] 10,11 * abstract *
 [A]  - YASHIMA E ET AL, "Continuous and Preparative Enantioseparation of Oxprenolol with Cellulose Tris(3,5-dimethylphenylcarbamate)-coated Belt", TETRAHEDRON ASYMMETRY, PERGAMON PRESS LTD, OXFORD, GB, (19950801), vol. 6, no. 8, doi:10.1016/0957-4166(95)00244-J, ISSN 0957-4166, pages 1889 - 1890, XP004048078 [A] 1-11 * the whole document *

DOI:   http://dx.doi.org/10.1016/0957-4166(95)00244-J
International search[X]US2012095070  (SPRINGER JOCHEN [DE], et al);
 [XP]WO2014016585  (PSIOXUS THERAPEUTICS LTD [GB]);
 [X]  - MARTÍNEZ-GÓMEZ M.A. ET AL., "Chiral separation of oxprenolol by affinity electrokinetic chromatography-partial filling technique using human serum albumin as chiral selector.", J PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (20050901), vol. 39, no. 1-2, pages 76 - 81, XP027718928
by applicantUS2005143378
 WO2007014219
    - WORMS PM., "The epidemiology of motor neuron disease: a review of recent studies", J Neurol Sci, (20010000), vol. 191, pages 3 - 9
    - WIJESEKERA LC; LEIGH PN, "Amyotrophic lateral sclerosis", Orphanet Journal of Rare Disease, (20090000), vol. 4, doi:doi:10.1186/1750-1172-4-3, page 3, XP021052313

DOI:   http://dx.doi.org/10.1186/1750-1172-4-3
    - RUTKOVE et al., Amyotroph Lateral Scler., (20120900), vol. 13, no. 5, pages 439 - 4
    - "The Industrial Synthesis of Optically Active Compounds", R. A. SHELDON, Problems and Wonders if Chiral Molecules, Akademiai Kiado, (19900000), pages 349 - 386
    - AUGUSTIAN J et al., Process Biochemistry, (20101000), vol. 45, no. 10, pages 1587 - 1604
    - YASHIMA E. et al., Tetrahedron: Asymmetry, (19950800), vol. 6, no. 8, pages 1889 - 1890
    - Eur J Drug Metab Pharmacokinet, vol. 23, no. 2, pages 178 - 84
    - BENNETT PN; BENNETT J; BRADBROOK I; FRANCIS J; JOHN VA; ROGERS H; TURNER P; WARRINGTON SJ. BR, J Clin Pharmacol., (19850000), vol. 19, no. 2, pages 171 S - 175S
    - WOODS KL; JACK DB; KENDALL MJ; HALSEY A; O'DONNELL ML; WARRINGTON SJ; JOHN VA. BR, J Clin Pharmacol, (19850000), vol. 19, no. 2, pages 177S - 184S
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.